Silo Pharma, Inc. (SILO)

0,9840 +0,0135 (+1,39%) Al cierre: 04:00PM EDT

Silo Pharma, Inc.

677 N. Washington Boulevard
Sarasota, FL 34236
United States
718 400 9031
https://silopharma.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 3

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Eric Weisblum	Chairman, President & CEO	569,01k	N/A	1970
Mr. Daniel E. Ryweck	Chief Financial Officer	62,69k	N/A	1965
Dr. James S. Kuo M.B.A., M.D.	Vice President of Research & Development	N/A	N/A	1965

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Gobierno corporativo

El ISS Governance QualityScore de Silo Pharma, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.